Similar articles for PMID: 9358593

Year	Number of Results
1993	1
1995	3
1996	2
1997	4
1998	4
1999	7
2000	11
2001	7
2002	6
2003	11
2004	10
2005	6
2006	3
2007	5
2008	1
2009	4
2010	3
2011	3
2012	4
2015	2
2017	1
2018	1
2023	0

1

The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy.

Stock RG, Stone NN. Stock RG, et al. Semin Surg Oncol. 1997 Nov-Dec;13(6):454-60. doi: 10.1002/(sici)1098-2388(199711/12)13:6<454::aid-ssu10>3.0.co;2-t. Semin Surg Oncol. 1997. PMID: 9358593

2

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N. Kollmeier MA, et al. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53. doi: 10.1016/s0360-3016(03)00627-8. Int J Radiat Oncol Biol Phys. 2003. PMID: 14529768

3

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Merrick GS, et al. Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73. doi: 10.1016/s0360-3016(01)02670-0. Int J Radiat Oncol Biol Phys. 2002. PMID: 11849788

4

Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.

Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Stock RG, et al. Cancer. 1996 Jun 1;77(11):2386-92. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2386::AID-CNCR30>3.0.CO;2-R. Cancer. 1996. PMID: 8635111 Clinical Trial.

5

PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.

Ko EC, Stone NN, Stock RG. Ko EC, et al. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. doi: 10.1016/j.ijrobp.2011.07.009. Epub 2011 Oct 8. Int J Radiat Oncol Biol Phys. 2012. PMID: 21985944

6

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Ho AY, et al. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 19289266

7

Isotope selection for patients undergoing prostate brachytherapy.

Cha CM, Potters L, Ashley R, Freeman K, Wang XH, Waldbaum R, Leibel S. Cha CM, et al. Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):391-5. doi: 10.1016/s0360-3016(99)00187-x. Int J Radiat Oncol Biol Phys. 1999. PMID: 10487561

8

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation.

Lee LN, Stock RG, Stone NN. Lee LN, et al. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):444-52. doi: 10.1016/s0360-3016(01)02598-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 11872291

9

Prostate brachytherapy: treatment strategies.

Stone NN, Stock RG. Stone NN, et al. J Urol. 1999 Aug;162(2):421-6. doi: 10.1016/s0022-5347(05)68574-6. J Urol. 1999. PMID: 10411050 Clinical Trial.

10

Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer.

Stone NN, Stock RG, Unger P, Kao J. Stone NN, et al. J Endourol. 2000 May;14(4):375-80. doi: 10.1089/end.2000.14.375. J Endourol. 2000. PMID: 10910155

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

94 results

Results by year